Endometrial cancer is the most common female genital cancer in the developed world. In the United States of America, an estimated 2.8% of women will be diagnosed with this malignancy at some point in their lifetime. Therefore, in order to improve the benefit of screening and the survival rate of patients, it is very important to establish a system of early diagnosis and targeted therapy for endometrial cancer. In the episode, we will give you a comprehensive introduction to endometrial cancer and its signaling pathways, diagnostic markers, and targeted therapies, as well as Creative Biolabs' antibody-related products and services.